JPWO2020005888A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020005888A5 JPWO2020005888A5 JP2020572388A JP2020572388A JPWO2020005888A5 JP WO2020005888 A5 JPWO2020005888 A5 JP WO2020005888A5 JP 2020572388 A JP2020572388 A JP 2020572388A JP 2020572388 A JP2020572388 A JP 2020572388A JP WO2020005888 A5 JPWO2020005888 A5 JP WO2020005888A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cycloalkynyl Chemical group 0.000 claims description 116
- 150000001875 compounds Chemical class 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 66
- 125000001188 haloalkyl group Chemical group 0.000 claims description 52
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 125000003342 alkenyl group Chemical group 0.000 claims description 46
- 125000000304 alkynyl group Chemical group 0.000 claims description 44
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 44
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 14
- 208000019622 heart disease Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 210000002235 sarcomere Anatomy 0.000 claims description 6
- 230000002861 ventricular Effects 0.000 claims description 6
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000028831 congenital heart disease Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 3
- 208000011518 Danon disease Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 2
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 230000009787 cardiac fibrosis Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690249P | 2018-06-26 | 2018-06-26 | |
| US62/690,249 | 2018-06-26 | ||
| PCT/US2019/038908 WO2020005888A1 (en) | 2018-06-26 | 2019-06-25 | Cardiac sarcomere inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529746A JP2021529746A (ja) | 2021-11-04 |
| JPWO2020005888A5 true JPWO2020005888A5 (enExample) | 2022-07-04 |
| JP7610985B2 JP7610985B2 (ja) | 2025-01-09 |
Family
ID=67211971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572388A Active JP7610985B2 (ja) | 2018-06-26 | 2019-06-25 | 心臓サルコメア阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12187712B2 (enExample) |
| EP (1) | EP3814343B1 (enExample) |
| JP (1) | JP7610985B2 (enExample) |
| WO (1) | WO2020005888A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067913T2 (hu) | 2018-01-19 | 2024-11-28 | Cytokinetics Inc | Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) * | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CA3190060A1 (en) | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| TW202339760A (zh) * | 2022-01-28 | 2023-10-16 | 韓商鐘根堂股份有限公司 | 用於預防或治療心臟衰竭(hf)之組合物 |
| US20250288586A1 (en) | 2022-04-26 | 2025-09-18 | MyoKardia, Inc. | Methods of Administering Myosin Inhibitors |
| CN120265616A (zh) * | 2022-09-26 | 2025-07-04 | 艾知怀斯治疗学公司 | 1,4-二氢喹唑啉酮化合物及其用途 |
| KR20250174911A (ko) | 2023-03-27 | 2025-12-15 | 엣지와이즈 테라퓨틱스, 인크. | 퀴놀리논 아미드 화합물 및 이의 용도 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2186371A1 (en) | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO2003059265A2 (en) | 2001-12-21 | 2003-07-24 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| WO2004064730A2 (en) * | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1606301A4 (en) | 2003-01-21 | 2006-06-14 | Archemix Corp | APTAMERIC THERAPEUTICS FOR MEDICINAL THERAPY FOR EYES |
| JP4969238B2 (ja) | 2003-03-27 | 2012-07-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| CA2529314A1 (en) | 2003-06-20 | 2005-07-07 | Amgen Inc. | Piperazine derivatives and methods of use |
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| EP1871755A1 (en) | 2005-04-22 | 2008-01-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| US20110275673A1 (en) | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| MY184008A (en) | 2009-05-15 | 2021-03-17 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US9493412B2 (en) | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| WO2014205234A1 (en) | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| CN109096274B (zh) | 2013-12-11 | 2022-07-01 | 比奥根Ma公司 | 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物 |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| CN111393414B (zh) | 2015-01-22 | 2024-05-07 | 迈奥卡迪亚公司 | 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 |
| US10501425B2 (en) | 2015-10-02 | 2019-12-10 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| CN108430997B (zh) | 2015-12-17 | 2021-06-04 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| CN108368098B (zh) | 2015-12-18 | 2022-01-28 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| WO2017190107A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| TWI764934B (zh) | 2016-09-27 | 2022-05-21 | 美商默沙東藥廠 | 作為mGluR2負向異位調節劑之色烷、異色烷及二氫異苯並呋喃衍生物、組合物及其用途 |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| JP2020023442A (ja) | 2016-12-19 | 2020-02-13 | 住友化学株式会社 | オキサジアゾール化合物及び植物病害防除方法 |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| US10981900B2 (en) | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
| RU2020109345A (ru) | 2017-08-04 | 2021-09-06 | Миокардиа, Инк. | Применение мавакамтена для лечения гипертрофической кардиомиопатии |
| HUE067913T2 (hu) | 2018-01-19 | 2024-11-28 | Cytokinetics Inc | Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók |
| CN112074505B (zh) | 2018-03-08 | 2024-04-05 | 因赛特公司 | 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53489A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| FI3999180T3 (fi) | 2019-07-17 | 2024-06-18 | Cytokinetics Inc | (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja |
| EP3999038B1 (en) | 2019-07-17 | 2024-01-10 | Cytokinetics, Inc. | Cardiac sarcomere inhibitor oral formulations |
| BR112022000523A2 (pt) | 2019-07-17 | 2022-03-03 | Cytokinetics Inc | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
| CA3190060A1 (en) | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| HUE070699T2 (hu) | 2021-07-16 | 2025-06-28 | Cytokinetics Inc | Afikamtén dózisadagolási obstruktív hipertrófiás kardiomiopátia kezelésére |
| US12077069B2 (en) | 2021-08-06 | 2024-09-03 | Dorel Juvenile Group, Inc. | Child restraint |
| US20250288586A1 (en) | 2022-04-26 | 2025-09-18 | MyoKardia, Inc. | Methods of Administering Myosin Inhibitors |
-
2019
- 2019-06-25 US US17/255,379 patent/US12187712B2/en active Active
- 2019-06-25 EP EP19737445.7A patent/EP3814343B1/en active Active
- 2019-06-25 WO PCT/US2019/038908 patent/WO2020005888A1/en not_active Ceased
- 2019-06-25 JP JP2020572388A patent/JP7610985B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020005888A5 (enExample) | ||
| FI90543B (fi) | Menetelmä lääkeaineina käyttökelpoisten dihydropyridiinin johdannaisten valmistamiseksi | |
| JP2002529532A5 (enExample) | ||
| JP2009527501A5 (enExample) | ||
| CZ318496A3 (en) | Substituted sulfonimidamides, process of their preparation, their use as a medicament or a diagnostic agent, as well as a medicament in which they are comprised | |
| JP2008081504A (ja) | 新規チアゾリジン−４−オン誘導体 | |
| JPH0613484B2 (ja) | 新規なジヒドロピリミジン類 | |
| JPWO2019144041A5 (enExample) | ||
| EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| FR2562892A1 (fr) | Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes | |
| CA2962922A1 (en) | Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | |
| US20020049205A1 (en) | Pyrazole antimicrobial agents | |
| JPWO2020047447A5 (enExample) | ||
| JPWO2020005887A5 (enExample) | ||
| EP2113502B1 (fr) | Composés de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires | |
| EP0109866A1 (fr) | Nouveaux dérivés de la sulfonylurée, leurs procédés de préparation et les compositions pharmaceutiques les renfermant | |
| WO2004000813A1 (ja) | フェノキシピリジン誘導体又はその塩 | |
| FR2545826A1 (fr) | Dihydropyridylimidates cycliques, et leur application pharmacologique | |
| JP2019507136A (ja) | カルボキサミドの製造方法 | |
| JPWO2022187501A5 (enExample) | ||
| JP2014503501A (ja) | 治療的有用性を伴う受容体調節因子としての新規化合物 | |
| HU191753B (en) | Process for preparing 5-acyl-2-/1h/-pyridinine deriva-tives | |
| JP2014509297A5 (enExample) | ||
| JPH0699458B2 (ja) | ジヒドロピリジン−５−ホスホン酸環状エステル類 | |
| EP0078545B1 (en) | imidazolecarboxylic acid derivatives |